Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inferring systemic exposure from a pharmacokinetic screen: model-free and model-based approaches

J R Nedelman1, A H Karara, C T Chang

  • 1Department of Clinical Pharmacology, Drug Safety, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

Statistics in Medicine
|May 15, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Psychiatric Care Provision for Children and Adolescents in Ireland.

Irish medical journal·2026
Same author

A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours.

ESMO open·2025
Same author

Exploring the Impact of Bullying and Friendship on Mental Health Outcomes Among Transgender, Gender Diverse (TGD), and Cisgender Lesbian, Gay, Bisexual (LGB+) Youth.

Journal of homosexuality·2025
Same author

SIFT IT: A feasibility and preliminary efficacy randomized controlled trial of a social cognition group treatment programme for people with acquired brain injury.

Neuropsychological rehabilitation·2024
Same author

Effectiveness of nirmatrelvir/ritonavir (Paxlovid®) in preventing hospitalisation and death among COVID-19 patients: a prospective cohort study.

The Medical journal of Malaysia·2023
Same author

Personality Assessment Inventory suicidality scales: Suicidal Ideation (SUI), Suicide Potential Index (SPI), and S_Chron in an Afghanistan/Iraq-era active and Veteran military sample.

Suicide & life-threatening behavior·2023

Two statistical methods were compared for analyzing drug exposure in clinical trials. A model-free approach offered similar results to a complex model-based method, proving easier and cheaper for assessing anxiolytic drug exposure.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Clinical Trial Statistics
  • Pharmacometric Modeling

Background:

  • Accurate assessment of systemic drug exposure is crucial for clinical trial analysis.
  • Phase III trials require robust methods to infer average and individual patient exposures.
  • Evaluating novel statistical approaches can optimize drug development processes.

Purpose of the Study:

  • To compare non-linear mixed-effect modeling (NLMEM) with a model-free approach for analyzing drug exposure in anxiolytic trials.
  • To determine the efficacy of a model-free method in estimating average and individual drug exposures.
  • To assess the practical advantages of different statistical methodologies in clinical trial settings.

Main Methods:

  • Application of non-linear mixed-effect modeling (NLMEM) to analyze systemic drug exposure.

Related Experiment Videos

  • Utilization of a model-free approach using quartiles of dose-normalized plasma concentrations.
  • Comparative analysis of the two methodologies in Phase III clinical trial data for a new anxiolytic.

    • Main Results:

    • The model-based approach provided deeper quantitative insights into exposure-covariate relationships.
    • The model-free approach yielded qualitatively similar results for average drug clearance.
    • The model-free approach demonstrated quantitatively similar estimations of individual drug exposures compared to NLMEM.
    • The model-free approach was found to be simple and cost-effective to implement.

    Conclusions:

    • A model-free statistical approach is a viable and efficient alternative to NLMEM for analyzing drug exposure in clinical trials.
    • The model-free method provides comparable results for key pharmacokinetic parameters and individual exposure estimations.
    • This finding supports the use of simpler, less resource-intensive methods for drug exposure analysis, particularly in large-scale trials.